Data / Drug companies / Cholestyramine
Cholestyramine: 14 companies and 26 products in the FDA NDC directory
Cholestyramine is listed in the FDA National Drug Code Directory by 14 companies, with 26 products in commercial distribution. 26 of the products (100.0%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are powder, for suspension, and the newest product started marketing on September 1, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 14
- Products
- 26
- Generic (ANDA) products
- 26 (100.0%)
- Application numbers
- 13
- Routes
- Oral
- Brand names
- Questran, Prevalite
- openFDA record search
- api.fda.gov
Companies that list cholestyramine
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Par Health USA, LLC | 4 | powder, for suspension | Generic drugs (ANDA) | September 15, 2005 |
| Epic Pharma, LLC | 3 | powder, for suspension | Generic drugs (ANDA) | December 15, 2021 |
| Bryant Ranch Prepack | 2 | powder, for suspension | Generic drugs (ANDA) | September 15, 2005 |
| Bryant Ranch Prepack | 2 | powder, for suspension | Generic drugs (ANDA) | September 15, 2005 |
| Macleods Pharmaceuticals Limited | 2 | powder, for suspension | Generic drugs (ANDA) | November 21, 2024 |
| Precision Dose, Inc. | 2 | powder, for suspension | Generic drugs (ANDA) | April 25, 2024 |
| Tagi Pharma, Inc. | 2 | powder, for suspension | Generic drugs (ANDA) | March 10, 2021 |
| Zydus Lifesciences Limited | 2 | powder, for suspension | Generic drugs (ANDA) | August 1, 2018 |
| Zydus Pharmaceuticals USA Inc. | 2 | powder, for suspension | Generic drugs (ANDA) | August 1, 2018 |
| AiPing Pharmaceutical, Inc. | 1 | powder, for suspension | Generic drugs (ANDA) | September 1, 2026 |
| Ajanta Pharma USA Inc. | 1 | powder, for suspension | Generic drugs (ANDA) | April 6, 2020 |
| Micro Labs Limited | 1 | powder, for suspension | Generic drugs (ANDA) | April 1, 2026 |
| Puracap Laboratories LLC DBA Blu Pharmaceuticals | 1 | powder, for suspension | Generic drugs (ANDA) | March 14, 2023 |
| Upsher-Smith Laboratories, LLC | 1 | powder, for suspension | Generic drugs (ANDA) | February 1, 1996 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Powder, for suspension | 26 | 100% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 26 | 100% |
Pharmacologic classes
| Class | Products |
|---|---|
| Bile Acid Sequestrant | 26 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.